PDCD1 and lung cancer: Immunotherapies have previously failed in lung cancer but has recently emerged as very effective new therapy [66], with the emergence of immune checkpoint blockade such as anti-PD-1 (programmed cell death-1) antibodies and anti PD-L1 (programmed cell death-ligand 1) antibodies [67].